ESMO 2014 Advanced Programme
Total Page:16
File Type:pdf, Size:1020Kb
esmocongress.org ADVANCED PROGRAMME ESMO 2014 Madrid, Spain 26-30 SEPTEMBER 2014 IMPORTANT DEADLINES 07 May 2014 Abstract submission and travel grant applications 18 June 2014 Early registration Organiser 23 July 2014 Group registration, participant names to be given 20 August 2014 Late-breaking abstract submission 20 August 2014 Late registration BASIC SCIENCE AND TRANSLATIONAL RESEARCH Saturday, 27 September 2014 Monday, 29 September 2014 10:30/ PATIENT CASES 11:00/ SPECIAL SYMPOSIUM 11:30 Cancer evolution: What can we learn from N=1 12:30 Genomic instability from bench to bedside molecular studies? Chair: Sheila Singh, Hamilton, ON, Canada Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, Co-Chair: Charles Swanton, London, UK London, UK Introduction Evolution of acute lymphoblastic leukemia (ALL) in identical twins Charles Swanton, London, UK Tariq Enver, London, UK The emerging role of HELQ in homologous recombination repair Clonal evolution of childhood cancers in ovarian cancer Michael Taylor, Toronto, ON, Canada Rebecca Burrell, London, UK Discussion Replication stress and DNA damage response in solid tumours Jiri Bartek, Copenhagen, Denmark The interface between cancer numerical and structural Sunday, 28 September 2014 chromosomal instability: Mechanisms accelerating cancer diversity 09:15/ JOINT SYMPOSIUM: ESMO - JSMO 10:45 How to implicate genome sequencing data in oncology René Medema, Amsterdam, Netherlands Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Targeting cancer aneuploidy: Light at the end of the tunnel? Atsushi Ohtsu, Kashiwa, Japan Tak Mak, Toronto, ON, Canada Introduction Conclusions and clinical perspectives Jean-Yves Douillard, St. Herblain, France Sheila Singh, Hamilton, ON, Canada Potentially druggable gene alterations in gastrointestinal cancer Tatsuhiro Shibata, Tokyo, Japan A new molecular taxonomy for colorectal cancer – What are the therapeutic implications? To be announced New insight of sequencing data in lung cancer Kazuto Nishio, Osaka, Japan Overcoming implementation challenges of personalised cancer therapy in patients with breast cancer Fabrice André, Villejuif, France Conclusions Atsushi Ohtsu, Kashiwa, Japan 13:00/ KEYNOTE LECTURE 13:45 Reclassifying cancer through genomics Chair: Jos Jonkers, Amsterdam, Netherlands Speaker: Michael Stratton, London, UK SCIENTIFIC COMMITTEE Charles Swanton, London, UK, Chair Jiri Bartek, Copenhagen, Denmark Jos Jonkers, Amsterdam, Netherlands René Bernards, Amsterdam, Netherlands Tak Mak, Toronto, ON, Canada Rebecca Burrell, London, UK Carlo Maley, San Franscisco, CA, USA Carlos Caldas, Cambridge, UK Sheila Singh, Hamilton, ON, Canada Robert Gatenby, Tampa, FL, US Yosef Yarden, Rehovot, Israel Ramaswamy Govindan, St. Louis, MO, US Session timings may be subject to change within the same day 9 BREAST CANCER Saturday, 27 September 2014 Sunday, 28 September 2014 09:00/ EDUCATIONAL SESSION 08:00/ PATIENT CASES 10:30 Update in the management of metastatic breast 09:00 Targeting intrinsic subtypes of metastatic breast cancers cancer: The spectrum of sensitivity to endocrine Chair: Angelo Di Leo, Prato, Italy therapy Co-Chair: Hernan Cortes-Funes, Madrid, Spain Co-Chairs: Philippe Bedard, Toronto, ON, Canada and Integration of molecular analyses in the management of Javier Cortes, Barcelona, Spain metastatic breast cancer Overcoming resistance in ER positive disease Nicholas Turner, London UK Philippe Bedard, Toronto, ON, Canada Hormonal therapy Dealing with heterogeneity of triple negative breast cancer: From Ian Smith, London, UK luminal androgen receptor to mesenchimal stem like subtype Optimal therapy for R2 positive Javier Cortes, Barcelona, Spain Angelo Di Leo, Prato, Italy Discussion 11:00/ EDUCATIONAL SESSION 09:15/ SPECIAL SYMPOSIUM 12:30 Management of breast cancer in specific populations 10:45 Residual disease after neoadjuvant therapies Chair: Fatima Cardoso, Lisbon, Portugal Chair: Evandro de Azambuja, Brussels, Belgium Co-Chair: to be announced Co-Chair: Suzette Delaloge, Villejuif, France Management of breast cancer in elderly patients Introduction Etienne Brain, Saint Cloud, France Suzette Delaloge, Villejuif, France Management of breast cancer in very young and pregnant Quantifying post-neo adjuvant therapy residual disease and its women impact on relapse risk Sybille Loibl, Neu-Isenburg, Germany Fraser Symmans, Houston, TX, US Management of breast cancer in males Biological profiling of residual disease Fatima Cardoso, Lisbon, Portugal Frederique Penault-Llorca, Clermont-Ferrand, France 16:00/ EDUCATIONAL SESSION (REPETITION) Molecular imaging: Are we able to predict for residual disease? 17:30 Management of breast cancer in specific populations Andreas Makris, Northwood, UK Chair: Fatima Cardoso, Lisbon, Portugal How to design clinical trials in a post neo-adjuvant setting? Co-Chair: to be announced Andrew Tutt, London, UK Management of breast cancer in elderly patients Conclusions and clinical perspectives Etienne Brain, Saint Cloud, France Evandro de Azambuja, Brussels, Belgium Management of breast cancer in very young and pregnant 14:15/ EDUCATIONAL SESSION (REPETITION) women 15:45 Update in the management of metastatic breast Sybille Loibl, Neu-Isenburg, Germany cancers Management of breast cancer in males Chair: Angelo Di Leo, Prato, Italy Fatima Cardoso, Lisbon, Portugal Co-Chair: Hernan Cortes-Funes, Madrid, Spain Integration of molecular analyses in the management of metastatic breast cancer Nicholas Turner, London UK Hormonal therapy Ian Smith, London, UK Optimal therapy for R2 positive Angelo Di Leo, Prato, Italy SCIENTIFIC COMMITTEE (EARLY STAGE) Evandro De Azambuja, Brussels, Belgium, Chair Hatem Azim, Brussels, Belgium Sabine C. Linn, Amsterdam, Netherlands Agusti Barnadas, Barcelona, Spain Carlo Palmieri, Liverpool, UK Fatima Cardoso, Lisbon, Portugal Alastair Thompson, Dundee, UK Boon Chua, Melbourne, Australia Andrew Tutt, London, UK Angelo Di Leo, Prato, Italy Giuseppe Viale, Milan, Italy Peter Dubsky, Vienna, Austria 10 Session timings may be subject to change within the same day Monday, 29 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 14:15/ JOINT SYMPOSIUM: ESMO - ESTRO - ESSO 09:00 Adjuvant treatment of breast cancer 15:45 Integration of local therapy with systemic treatment in Speaker: Martine Piccart, Brussels, Belgium oligometastatic breast cancer Co-Chairs: Christoph Zielinski, Vienna, Austria; Philip Poortmans, 09:15/ SPECIAL SYMPOSIUM Tilburg, Netherlands and Riccardo A. Audisio, St. Helens, UK 10:45 Cancer immunotherapy in breast cancer: Dream or Introduction reality? Christoph Zielinski, Vienna, Austria Chair: Giuseppe Curigliano Milan, Italy Co-Chair: Sherene Loi, Melbourne, Australia Combining systemic treatment with radiation therapy: Quantifying the therapeutic gain Introduction Per Karlsson, Gothenburg, Sweden Giuseppe Curigliano Milan, Italy Design of clinical trials integrating local treatments with systemic Modulation of immune response in breast cancer and clinical therapy for M1 disease implications of tumour dormancy To be announced Sherene Loi, Melbourne, Australia The role of surgery for M1 breast cancer Diagnostic and therapeutic implications of tumour-infiltrating lymphocytes in breast cancer Marjut Leidenius, Helsinki, Finland Carsten Denkert, Berlin, Germany The role of radiation therapy for M1 breast cancer Philip Poortmans, Tilburg, Netherlands Contribution of immune response to anti-tumour effect of chemotherapy Conclusions Carmen Criscitiello, Naples, Italy Riccardo A. Audisio, St. Helens, UK Design of the ideal trial with immunotherapeutics 16:00/ PATIENT CASES Giuseppe Curigliano Milan, Italy 17:00 Challenges in managing breast cancer in young Conclusions and clinical perspectives patients Sherene Loi, Melbourne, Australia Co-Chairs: Hatem A. Azim, Brussels, Belgium; Marco Colleoni, Milan, Italy and Sabine Linn, Amsterdam, Netherlands Genetic testing: When and for whom? Sabine Linn, Amsterdam, Netherlands Fertility counselling: What are the options? Hatem A. Azim, Brussels, Belgium, Optimal adjuvant hormonal therapy in premenopausal women Marco Colleoni, Milan, Italy Discussion Tuesday, 30 September 2014 08:00/ CYE (REPETITION) 09:00 Adjuvant treatment of breast cancer Speaker: Martine Piccart, Brussels, Belgium SCIENTIFC COMMMITEE (METASTATIC) Giuseppe Curigliano, Milan, Italy, Chair Philippe Bedard, Toronto, ON, Canada Per Karlsson, Gothenburg, Sweden Javier Cortes, Barcelona, Spain Antonio Llombart, Valencia, Spain Carmen Criscitiello, Milan, Italy Sherene Loi, Melbourne, Australia Carsten Denkert, Berlin, Germany Sibylle Loibl, Neu-Isenburg, Germany Luca Gianni, Milan, Italy Nicholas Turner, London, UK Roger Gomis, Barcelona, Spain Session timings may be subject to change within the same day 11 CNS TUMOURS Sunday, 28 September 2014 09:15/ EDUCATIONAL SESSION 14:15/ SPECIAL SYMPOSIUM 10:45 Actual issues in neurooncology 15:45 Current concepts and future avenues in meningioma Chair: Roger Stupp, Zurich, Switzerland Chair: Jörg-Christian Tonn, Munich, Germany Co-Chair: Mario Campone, St. Herblain, France Co-Chair: Matthias Preusser, Vienna, Austria Brain metastases: To treat or not to treat? Introduction Roger Stupp, Zurich, Switzerland Jörg-Christian Tonn, Munich, Germany Molecular marker-based clinical decision-making today Meningioma: What can we learn from the biology for precision Michael Weller, Zurich, Switzerland medicine? Approaches to recurrent glioblastoma Michel Kalamarides, Paris, France Alba Brandes, Bologna, Italy Classification and molecular